Bajaj Healthcare Ltd. (BAJAJHCARE) — Tipsheet

Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers

Tipsheet Editorial — Mon, 20 Jul 2026 20:51:47 GMT

Domestic API sales jumped 27% but exports slipped. The press release adds nothing new beyond the board outcome.

What’s new

Revenue ₹165.6 cr, up 11.3% YoY
PAT ₹13.7 cr, up 15.8% YoY
Domestic API sales grew 27%
SEC recommended Cenobamate tablets

Why it matters

A routine confirmatory filing. The real news—domestic API growth and the Cenobamate recommendation—was already released via the board outcome. With a trailing P/E of 48 and negative trailing PAT growth, consistency in domestic API performance is the key to re-rating.

What we’re watching

Earnings call on July 21 for management commentary on export API decline
Cenobamate tablet approval timeline and commercial launch
Sustained domestic API momentum and margin trajectory

The full read

Bajaj Healthcare's Q1 numbers were already out. The press release today confirms revenue of ₹165.6 crore, up 11.3%; PAT of ₹13.7 crore, up 15.8%; and an EBITDA margin of 17.8%. Domestic API sales jumped 27%, while export API and formulations slipped. The filing also notes an SEC recommendation for Cenobamate tablets, a pipeline item that adds optionality but no near-term revenue. The open question is whether domestic API momentum is sustainable. Hardly a surprise. The stock trades at 48x trailing earnings. Profitability needs to follow the topline. The call on July 21 may offer clues on both fronts.

Primary source: BSE · NSE

Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%

Tipsheet Editorial — Mon, 20 Jul 2026 19:45:49 GMT

Standalone revenue from continuing operations rose to ₹165.63 crore in the June 2026 quarter; board also approved continuation of independent director beyond age 75.

What’s new

Revenue from continuing ops rose 11% YoY to ₹165.63 cr
PBT from continuing ops increased to ₹16.46 cr from ₹14.53 cr
Board approved continuation of independent director Gopalakrishnan Kesavan post-75

Why it matters

The growth is modest and in line with recent trends, unlikely to shift the narrative for a stock trading at a P/E of 47.8. The director approval is standard governance. This is a routine quarterly update with no surprise.

What we’re watching

Sustainability of revenue growth in coming quarters
Any improvement in ROE and debt reduction
Potential for new product approvals or contract wins

The full read

Bajaj Healthcare reported a modest uptick in Q1 FY27. Standalone revenue from continuing operations came in at ₹165.63 crore, up 11% year-on-year, while PBT improved to ₹16.46 crore from ₹14.53 crore. The board also approved the continuation of independent director Gopalakrishnan Kesavan beyond age 75 — a routine governance item. For a stock trading at 47.8 times trailing earnings, this quarter's steady but unspectacular growth does little to justify the premium. With trailing revenue and PAT both deeply negative, the company has ground to make up before the narrative shifts. Expect a neutral market reaction.

Primary source: BSE · NSE